T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
Non-small Cell Lung Cancer
About this trial
This is an interventional diagnostic trial for Non-small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Age greater than or equal to 18 years
- Histologically or cytologically documented stage I-IIIA non-small cell lung cancer (NSCLC)
- Eligible for with plan to undergo immunotherapy alone or both immunotherapy and stereotactic radiation therapy as part of NCT03217071
- In female patients, negative pregnancy test with no plans to become pregnant during the duration of the study
- Able to provide informed consent and follow the study guidelines
Exclusion Criteria:
1. Female patients who are pregnant or breastfeeding
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Cohort 1 - Immunotherapy Alone
Cohort 2 - Immunotherapy with Stereotactic Radiation
Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.